Wire Stories

Category Added in a WPeMatico Campaign

Elpiscience_logo_PNG

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-? Bispecific Antibody ES014

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology...

Biocytogen27s_LOGO-1

Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

BEIJING--(BUSINESS WIRE)--#Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co.,...